←Back to Expert Scholars
Translational Medicine / 转化医学Rare Adult Tumors, Uveal Melanoma
Richard Carvajal
MD
🏢Northwell Health Cancer Institute🌐USA
Deputy Physician-in-Chief, Director, Melanoma Service
68
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Richard Carvajal led pivotal trials of tebentafusp establishing the first overall survival benefit in metastatic uveal melanoma. He has advanced understanding and therapy of rare melanoma subtypes including mucosal and acral disease. He is a global authority on uveal melanoma drug development.
Share:
🧪Research Fields 研究领域
uveal melanoma
tebentafusp
HLA-A*02:01 ImmTAC
metastatic uveal melanoma
rare melanoma subtypes
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Richard Carvajal 的研究动态
Follow Richard Carvajal's research updates
留下邮箱，当我们发布与 Richard Carvajal（Northwell Health Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment